Around 2007 - 2009, two different BCI stories were happening simultaneously. In one, cheap EEG headsets were showing up at CES under the label “mind control.” In the other, DARPA was quietly funding the labs and programs that would define serious BCI research for the next decade. The public story and the scientific story diverged here… and they’ve never fully reconnected.

In this post, I’m closing Phase 1 of this series by looking at the funding and cultural landscape that framed BCI research at the end of its first decade. The consumer neurotech wave created public awareness and a developer ecosystem, but also expectations the field couldn’t meet. The DARPA investment created capabilities and talent pipelines the field still draws on. Understanding both helps explain why BCI has this particular relationship with hype, and why that relationship keeps repeating.

Consumer neurotech arrives

The Emotiv EPOC launched in 2009. It was a 14-channel wireless EEG headset retailing around $299, marketed toward game developers and tech enthusiasts under the tagline “Emotiv - Experience Your Emotions.” The demo videos showed people controlling virtual objects and characters with facial expressions, head movements, and “cognitive” signals decoded from the EEG. This last factor was heavily promoted by the company. The device appeared at gaming expos, technology conferences, and, critically, in mainstream media coverage framed around “mind control.”

NeuroSky’s MindWave launched around the same period, even simpler: a single-channel EEG device that measured attention and relaxation states (really, frontal electrode power in the alpha and beta bands) and translated them into game control signals. Price point: around $80. NeuroSky’s SDK made it easy for developers to build applications, and it did! There was a small ecosystem of BCI games and biofeedback apps within a year or two of launch.

The honest accounting of what these devices could do is this: they could measure gross EEG features (alpha power, beta power, muscle artifacts, blink detection) with reasonable reliability. The Emotiv EPOC’s “cognitive” detection was largely trained on facial muscle EMG and head movement, not pure EEG. Neither device was capable of the kind of motor imagery decoding that the Graz group was doing in research labs with 64-channel systems and trained subjects. The “mind control” framing was marketing language, not a technical description.

None of that stopped the coverage. The phrase “reading your brain” appeared in headline after headline. Popular magazines ran features about mind-controlled games and “thought-powered” computers. The gap between what the devices could do and what the coverage implied was wide, but the story was too compelling to resist. A $300 headset. Mind control. Available now. The field got the attention it had never had from the $100 million NIH-funded work.

What the consumer devices did accomplish, which deserves credit: they introduced a generation of software developers and hardware hackers to EEG as a platform. Hackathons built BCI games. Makers modified the Emotiv EPOC’s firmware. OpenBCI, which would later become a serious open-source EEG hardware platform, grew partly from this ecosystem of people who had gotten their first exposure to neural signal acquisition through consumer headsets. The technology was crude. The pipeline it seeded was real.

DARPA and the serious money

The most consequential was the Revolutionizing Prosthetics program, launched by DARPA in 2006. The goal was explicit and ambitious: build a prosthetic arm that could be controlled by thought, with sensory feedback, with performance approaching a natural limb. DARPA funded two parallel teams:

• one at the Applied Physics Laboratory at Johns Hopkins (APL)

• one at DEKA Research (Dean Kamen’s company)

to develop the hardware while research labs including BrainGate worked on the neural control interface. The APL arm, eventually called the Modular Prosthetic Limb, was a 100-degree-of-freedom device with individual finger control, shoulder and elbow joints, and force sensors. DEKA produced what became the FDA-approved DEKA Arm in 2014. The Revolutionizing Prosthetics program set a concrete engineering target and funded the work to reach it. That’s how DARPA works when it’s working well.

DARPA’s broader involvement in BCI research in this period ran through the Human Assisted Neural Devices (HAND) program and later programs covering cortical implants, sensory feedback, and neural decoding. The agency’s model was compatible with the risk profile of early BCI: long time horizons (5–10 year programs), high risk tolerance, willingness to fund academic labs directly, and an explicit preference for demonstrations rather than papers. The BrainGate work at Brown and MGH received DARPA and NIH funding throughout this period, as did Schwartz’s lab at Pittsburgh, Shenoy’s at Stanford, and Andersen’s at Caltech. The talent pipeline those labs produced → PhD students, postdocs, and research scientists funded directly or indirectly by DARPA and NIH grants → went on to found or lead many of the BCI companies that would emerge in the 2010s and 2020s.

The BCI Competition datasets deserve mention in this context. The competitions were organized by a European consortium of labs and run in 2003, 2005, and 2008. These competitions were a form of public good that government and academic funding made possible. They distributed labeled EEG, ECoG, and LFP datasets to the research community and scored blind test-set performance, creating the shared benchmarks the field needed. The BCI Competition IV’s 2008 datasets (four-class motor imagery, continuous ECoG cursor control, and MEG decoding) attracted competitive algorithm submissions from dozens of groups globally. Common spatial pattern filtering emerged as the clear winner for motor imagery EEG decoding, cementing its use across the non-invasive BCI community for the following decade. Without public funding and academic organization, those datasets wouldn’t have existed, and the field’s algorithmic progress would have been slower and harder to compare.

The expectations gap

When Emotiv and NeuroSky were getting breathless press coverage about mind control in 2009, the BrainGate team was doing something far more modest: managing an IDE-approved clinical trial with a handful of participants, under strict FDA oversight, producing cursor control that required daily recalibration and a trained technician. When the consumer narrative implied that BCI was a solved problem available at your local electronics store, it made the actual research look like it was failing to deliver. It created an implicit benchmark of “why can’t this device do what that $300 headset promised?” that bore no relationship to what the science was actually attempting.

The expectations gap created a recurring pattern: consumer products would make dramatic claims, media coverage would amplify them, public expectations would rise, and then the scientific community would spend years explaining why those expectations were wrong. This cycle has repeated with every generation of consumer neurotech since. The Muse meditation headband in the early 2010s. The various “focus enhancement” EEG startups. And more recently, the broader consumer wellness EEG market. Each iteration generated attention and some developer ecosystem activity; none delivered what the marketing implied.

The more structurally important point is that this divergence left BCI research in an odd position:

• enormous public interest, persistent media attention, a growing community of hobbyists and developers

• simultaneously, a clinical and commercial reality that lagged far behind those expectations

The field was pre-commercial and pre-regulatory for cortical devices. No BCI startup had found a sustainable business model outside cochlear implants and DBS. The academic labs doing the serious work were largely invisible to the audiences the consumer products had cultivated.

Why it mattered

Consumer devices created a pipeline of people who cared about BCI before it was clinical. Some of the developers who built Emotiv applications in 2010 became the BCI engineers of the 2020s. The hobbyist community kept BCI visible during years when the clinical pipeline was slow and opaque.

DARPA funding built the labs, trained the students, and funded the electrode technology and prosthetic hardware that today’s companies are commercializing. Blackrock Microsystems, the company that acquired Cyberkinetics’ manufacturing assets in 2008 and became the dominant supplier of Utah Arrays to research labs, exists because of that funding ecosystem. The Modular Prosthetic Limb from APL became the hardware platform for multiple BrainGate demonstrations. The Kalman filter for neural decoding, now standard, was developed and refined in DARPA-funded labs. Federal investment in long-horizon, high-risk research created capabilities that private capital wouldn’t have funded and that no startup was positioned to build.

The expectations gap, though, became a structural feature of the field. Every major BCI moment since (Neuralink’s first announcement, BrainGate’s robotic arm demonstrations, Synchron’s first human implant) has involved a negotiation between what the public story says and what the science actually shows. That negotiation is exhausting for researchers and often produces either over-promising or defensive under-claiming. It’s not unique to BCI; it’s a common pattern in fields where the technology is genuinely important but the timelines are genuinely long. But the 2008–2010 period is where it crystallized.

What was still uncertain

Whether consumer EEG would ever cross from novelty to utility was genuinely open. The honest answer in 2010 was probably no, because the device quality and the algorithmic approaches available at consumer price points weren’t close to clinical reliability. It was not because EEG signals were useless. The market for EEG-based games and meditation apps was real but small. The pathway from consumer curiosity to clinical adoption was unclear.

Whether DARPA-funded research would translate to civilian commercial products was also uncertain. The Revolutionizing Prosthetics program produced impressive hardware. Whether that hardware would find commercial and regulatory pathways to reach the patients who needed it was a different question. The FDA-approval gap for neural devices made this particularly murky. The DEKA Arm’s eventual 2014 FDA clearance was a validation of the program, but it took eight years from DARPA launch to approval, and even then commercial deployment remained limited.

The academic-dominated structure of the field had virtues (long time horizons, scientific rigor, openness) but it had real limits. Academic labs couldn’t manage clinical trials at scale, couldn’t iterate product designs rapidly, couldn’t build the manufacturing, regulatory, and commercial infrastructure that devices eventually required. The startup wave was coming, but as of 2010 it was still years away.

Phase 1 in eight years

By the end of 2010, BCI had gone further than most people outside the field realized… and less far than the public narrative implied. Matthew Nagle had moved a cursor with his thoughts in 2004. BrainGate had published in Nature in 2006. The Utah Array had been in human brains for years. ECoG had revealed unexpected signal richness on the cortical surface. Cochlear implants had proved that neural interfaces could be safe, durable, and routine. A generation of developers had gotten their first EEG exposure from consumer headsets.

What it didn’t have: a commercial product for motor restoration, a reimbursement pathway, a second clinical success at anything approaching cochlear implant scale, or a realistic near-term path to home use for intracortical devices. The field was scientifically successful and commercially nascent.

Phase 2 starts with a catalyst from outside neuroscience entirely. In the early 2010s, deep learning began transforming how neural signals could be decoded. Advancement was not through better electrode technology or better surgical approaches, but through better mathematics applied to the data the existing hardware was already collecting. That’s the next post.

Source material

Yearly reviews

• 2007 review

• 2008 review

• 2009 review

• 2010 review

Monthly feeds (key months)

• 2007-09

• 2008-01

• 2008-06

• 2009-01 — CES / Emotiv period

• 2009-06

• 2010-03

• 2010-12 — end of Phase 1 landscape

Topic pages

• consumer-neurotech-era

• muse-interaxon

• neurotech-funding-industry

• neurotech-industry-and-market

• bci-development-costs

• motor-imagery-eeg-bci

• neuroprosthetics-and-rehabilitation

• brain-health-assessment-military-neurotechnology

No Neuralink update, no FDA clearance, no megaround this week either. Consumer neurotech got the headlines, but the substance sits in interface mechanics, signal-quality work, and a couple of methods critiques that the field has been overdue to have.

The paper worth reading first

An intelligent EEG-based ensemble framework for communication assistance in Locked-In Syndrome patients
Scientific Reports, April 2026

Twenty participants, visual P300, five-phrase selection. A soft-voting ensemble of SVM + random forest on discrete wavelet transform features reaches 97.5% offline accuracy, against 92.5% for SVM alone and 89% for RF alone.

The offline number is strong. The question the paper doesn’t answer is the one that decides whether this matters clinically: online information transfer rate. No bits per minute. No fatigue curve. No calibration burden across sessions. Earlier P300 work in disabled cohorts has been clear for a decade → single-trial behavior, repetition load, and calibration dominate usability in ways that offline accuracy doesn’t capture.

So: good offline assistive result. Not yet evidence that non-invasive communication BCIs have solved the problem locked-in users actually face.

The hardware story of the week

3D-printed “honeycomb” cortical sensors, personalized to individual neural maps
Penn State, April 2026

Patient-specific hydrogel electrodes with a honeycomb structure, 3D-printed to conform to individual cortical folds. The framing is better contact and better tissue compatibility through per-patient geometry, not through adding channels.

Why this matters beyond the press release: chronic interface performance is largely a mechanics problem. Mismatch and micromotion drive gliosis. Gliosis drives impedance and signal drift. That’s the failure mode that quietly kills long-term recording, and it’s not something a bigger decoder fixes.

The companion non-invasive paper this week underlines the same point from the scalp side. A systematic evaluation of EEG electrode geometry (Scientific Reports, April 2026) frames electrode shape and placement as part of the measurement, not an interchangeable front end. Geometry sets part of the ceiling on SNR and spatial sampling, which sets part of the ceiling on whatever pipeline follows.

Hardware is becoming algorithmic leverage, not a materials side quest.

Methods under pressure

Two different warnings about technical overconfidence landed in the same week.

Brain-computer interfaces: an engineering black-box swindle or a lone advance guided by deep learning (Frontiers in Neuroscience, April 2026) reads as a demand for hygiene rather than an attack on deep learning → transparent ablations, application-matched evidence, benchmark discipline before declaring progress. Black-box gains are easy to celebrate on narrow datasets and forgiving evaluation. They’re much harder to defend across users, across sessions, and under regulatory review.

Overdue debate unfurls over neuroimaging method (The Transmitter, April 2026) tracks the fallout from the January Nature Neuroscience critique of lesion network mapping, which argues many results reflect generic connectome structure rather than disorder-specific biology. A February rebuttal preprint argues specificity holds under careful reanalysis.

The takeaway isn’t “throw the method out.” It’s that if a network inference will later influence stimulation targets or mechanistic claims, the specificity burden needs to rise.

Aperiodic signals are real, and easy to overread

An inhibitory circuit motif governs oscillation-dependent coupling between aperiodic activity and neural spiking
bioRxiv, April 2026

Optogenetics plus simultaneous single-unit and LFP recordings in mouse visual cortex. The authors identify an inhibitory motif that governs how aperiodic LFP activity couples to spiking, and show the coupling is oscillation-dependent → the relationship is real but conditional on state and regime.

Aperiodic and broadband features keep showing up in decoders, biomarkers, and closed-loop controllers as if they’re simple proxies for excitability. This preprint is the cleanest argument yet that they aren’t. A feature can be predictive and still be misinterpreted. For closed-loop work, that distinction has product consequences, not just scientific ones.

Broadband gamma-band EEG changes during magnetophosphene perception induced by 20 Hz magnetic field stimulation (bioRxiv, April 2026, n=13) lands nearby. Percept-linked effects may appear as distributed broadband gamma changes rather than tidy narrowband markers. Same methodological moral from a different angle.

Speech decoding’s preprocessing problem

Correction: Appropriate data segmentation improves speech encoding models
PLOS ONE, April 2026

Looks like housekeeping. It isn’t.

Bialas and Lalor show that segmentation choices change what a speech encoding model appears to learn from electrophysiological recordings. Which means some fraction of what gets reported as architecture superiority in iEEG/ECoG speech benchmarks is actually a stationarity or windowing decision wearing a model’s clothes.

If segmentation moves the result, segmentation is part of the claim. This is a healthy correction for a subfield whose benchmark narratives have been drifting away from the preprocessing assumptions that make them possible.

The consumer neurotech noise floor

This Beanie Is Designed to Read Your Thoughts
WIRED, April 2026

Sabi launched a non-invasive thought-to-text beanie. Coverage in WIRED, Startup Ecosystem Canada, and The News references high sensor counts and ~30 wpm targets. No peer-reviewed imagined-speech validation yet.

Track it as commercialization signal, not verified capability. What it tells you is what the market thinks matters now → comfort, invisibility, and a path out of lab aesthetics. That’s useful intelligence. It’s not evidence of decoding.

Also on the radar

Physiologically inspired modeling of cortical dynamics through spiking neural networks (J. Neural Engineering) — SNN framework for inferring cortical network dynamics from scalp EEG. Sits near the forward/inverse problem and pushes EEG analysis toward mechanism-linked latents rather than pure black-box decoding.

Designing Implants that Don’t Scar the Brain (Neuroscience News) — Popular summary, but the mechanical-mismatch framing matters for any ECoG or depth-array program. Pair with the primary polyimide biostability literature.

EEG-based stroke severity classification using higher-order topological features and graph convolutional networks (Frontiers in Neuroscience) — Persistent-homology features on EEG functional networks, combined with GCNs. Not a BCI paper, but the feature-engineering path overlaps.

Mid-superior temporal sulcus encodes spatial context and behavioral state in freely moving macaques (bioRxiv) — Wireless depth recording during naturalistic 3D behavior. Future intracranial BCIs need robustness outside constrained tasks. This is one of the cleaner datasets on that axis.

Discovering Novel Circuit Mechanisms in Higher Cognition through Factor-Centric Recurrent Neural Network Modeling (bioRxiv) — Restricted-RNN framework for interpretable latent dynamics. Methodologically adjacent to state estimation for decoders.

Exploring individual biases in BCI research and users: Does gender matter? (Frontiers in Human Neuroscience) — Cohort imbalance is a model-validity problem for adaptive decoders, not only an ethics note.

A roadmap to competitive preclinical packages (Nature Medicine) — Integrating evidence streams for IDE/IND-adjacent packages. Useful framing for neural-device sponsors.

AI Restores Voices Through Microscopic Neck Movements (Neuroscience News) — Wearable speech restoration from neck movements. Not a BCI. Worth watching as a comparator class where non-neural pathways may beat neural ones on usability and deployment speed.

What I’m following up on

• Locked-in P300 ensemble paper: online ITR, calibration burden per session, fatigue tolerance. None of these are in the abstract.

• Honeycomb cortical electrodes: primary materials paper, stiffness match against cortex, longevity data beyond acute.

• FORCE1s / GEVI follow-through from week 15: tracking toward journal submission and ASAP4 benchmarks.

• Lesion-network debate: waiting on responses from the method’s primary proponents and any re-analyses with stricter specificity controls.

• Sabi: any peer-reviewed imagined-speech validation, or independent replication of the wpm claim.

My take

Quiet week for news. Useful week for boundaries.

The locked-in P300 paper is a good offline result that hasn’t demonstrated deployment. The honeycomb electrode work is a reminder that contact mechanics sit upstream of everything downstream. The deep-learning-in-BCI piece and the lesion-network debate are the same message in two different registers → convenient abstractions need stricter tests before they influence clinical or product decisions. The aperiodic-coupling preprint says the broadband features we like to read as excitability are conditional on state and circuit context. The PLOS segmentation correction says part of speech-decoding benchmark performance is a preprocessing choice.

The through-line: the bottleneck is stability, transfer, and honest evaluation, not another aggregate accuracy number.

This was a quiet week for launches, rounds, and trials. No Neuralink update, no FDA clearance, no megaround. If you’re scanning for that kind of signal, you won’t find it here.

What you will find is a methods week that actually matters. Two optical voltage indicators. A new tACS hardware system with real impedance validation. A PNAS paper that addresses a question the field has been circling for decades. And a $24M Canadian neuroprosthetics initiative that deserves more attention than it’s getting.

The paper worth reading first

BCI-based neurofeedback training enables transferable control of cortical state switching in humans
PNAS, April 2026

Closed-loop regulation of sensorimotor activity has been possible since the 1960s. The question that hadn’t been settled: can people learn to switch cortical states volitionally, and does that learned control transfer → meaning it generalizes beyond whatever training setup produced it?

This paper says yes.

The transfer result is what makes it interesting. Most neurofeedback work shows that people can learn to modulate a signal in a specific context. Fewer papers ask whether that control extends when the context changes. If it does, the implications for decoder longevity and session-to-session calibration are direct: users who build genuine state-switching skill may need less recalibration over time.

The clinical story of the week

Dr. Christian Iorio-Morin — From Gamma Knife to Neuroprosthetics: The Future of Functional Neurosurgery
Neural Implant Podcast, April 2026

Dr. Iorio-Morin is a functional neurosurgeon and professor at the Université de Sherbrooke. The episode covers movement disorders, chronic pain, gamma knife, and neuroprosthetics. But the real reason to listen is RE-MOVE.

RE-MOVE is a 14-investigator interdisciplinary project, awarded a $24M grant from Canada’s New Frontiers in Research Fund (Transformation stream). The core problem it’s solving: spinal circuits responsible for muscle control often survive injury intact. The failure is signal interruption, not the loss of the muscles or neurons themselves. RE-MOVE builds a bridge → cortical or spinal sensors detect movement intention, and neuromodulation activates the paralyzed limbs.

The system uses cortical sensors, haptic gloves, and human-machine interfaces. It was designed from the beginning with “ethics by design”; law and ethics are integrated into the research structure, not retrofitted after the engineering is done.

This is Canada’s most-resourced closed-loop neuroprosthetics initiative currently active. It hasn’t gotten the coverage it deserves outside of the Québec academic press. Worth tracking.

The tooling news: two GEVI preprints in the same week

Two bioRxiv preprints dropped this week targeting the same bottleneck: two-photon voltage imaging with genetically encoded voltage indicators (GEVIs) hasn’t been practical enough for most labs.

FORCE1s — accessible two-photon recordings in vivo

FORCE1s is a green, positive-going GEVI that brightens from a dark baseline during depolarization. In awake mice, it reports spikes at approximately 100% ΔF/F. The “accessible” framing is substantive: it works on standard resonant-scanning microscopes, not just specialist hardware. It also supports MEMS-based two-photon miniscopes for freely moving mice and multiplexed voltage-neurotransmitter imaging. The equipment bottleneck is the main reason GEVI adoption has been slow. FORCE1s directly targets that.

Designer indicators for subthreshold voltage dynamics

The companion preprint pushes further: subthreshold voltage (the integration layer below spike threshold) has been nearly inaccessible with two-photon GEVIs because sensitivity is too low for millivolt-scale signals. This work reports a multiparametric refinement approach to close that gap.

Together, these two preprints represent a coordinated tooling push: spike-resolved readout on accessible hardware (FORCE1s), plus subthreshold dynamics for richer ground-truth data. Both are preprints, so replication and journal review pending. But for labs choosing optical recording stacks, these are the ones to track.

tACS hardware gets a real validation standard

PD-stim — phase-difference tACS system for dual-site neuromodulation
Frontiers in Neuroscience, April 2026

Dual-site transcranial alternating current stimulation (tACS) requires precise phase control between stimulation sites. Conventional setups often lack it. Prior validation work is seldom done under realistic biological impedance conditions.

PD-stim addresses both problems: programmable inter-regional phase-difference stimulation with impedance-aware hardware validation.

Why phase precision matters: recent beta-band ds-tACS work shows in-phase stimulation and anti-phase stimulation produce opposite effects. In-phase enhances fronto-motor connectivity and predicts better inhibitory control; anti-phase reduces connectivity and speeds go responses. The direction of effect flips based on the phase relationship. A system without stable phase control can’t reliably reproduce those results. PD-stim is the platform that makes this class of experiments reproducible at scale.

A second tACS paper this week (Scientific Reports) reported that network-nodal tACS induces right-lateralization of thalamocortical connectivity. Connectivity readout is still a proxy, and site/frequency specificity is unresolved… but it’s another data point that non-invasive network-level stimulation produces measurable, directional effects.

Also on the radar

Epidural and DRG stimulation in SCI: therapy-specific motoneuron activation (JNP) — Recruitment is selective, not uniform, and shifts with stimulation parameters. Not a decoding BCI study, but directly relevant to the stimulation side of RE-MOVE-class systems.

Motor unit firing rates persist during neurofeedback (JNP) — Motor-unit firing-rate structure in tibialis anterior is preserved, not reorganized, during neurofeedback. Practical constraint for motor-BCI signal interpretation: feedback may not reshape the firing distributions that some decoder designs assume it will.

Combined electrophysiology + functional ultrasound: roadmap review (JNP) — fUSI’s whole-brain spatial coverage combined with electrophysiology’s temporal precision is a compelling pairing for chronic closed-loop interfaces. This review maps the practical tradeoffs. Still mostly a pre-human-trial modality, but the roadmap is clear.

EEG data augmentation survey (Frontiers in Neuroscience) — Systematic review on augmentation strategies for EEG emotion recognition and cognitive workload decoding. Prior work shows augmentation improves EEG decoding by ~29% on average; this survey organizes the taxonomy and flags task-specific pitfalls. Now the canonical starting reference for this problem.

sEMG bulbar assessment in ALS (Frontiers in Neuroscience) — 60 quantitative features from six craniofacial muscle groups, fully automated. Directly relevant to speech-BCI candidacy: objective bulbar stratification determines who is a viable candidate for speech-motor neuroprosthetics and when in disease progression to intervene.

Error equation predicts the brain’s ability to generalize (The Transmitter) — Four statistical measurements of neural network geometry predict generalization in both biological and artificial networks. Trade-press summary, primary paper still needed, but the bridge between ML-style generalization metrics and neuroscience is a useful conceptual frame for decoder design.

What I’m following up on

• PNAS neurofeedback: Need full text to extract training duration, signal type, and transfer paradigm specifics. Would someone send me the paper?

• FORCE1s: Tracking toward journal submission; benchmark comparison against ASAP4 GEVIs and rhodopsin-based 2P indicators.

• RE-MOVE: Watching for ClinicalTrials registrations and first human-implant protocol publications from the Sherbrooke team.

• PD-stim: Does the supplement include E-field characterization data comparable to the prior HD ds-tACS validation literature?

My take

Thin week for news. Strong week for boundaries.

The best work here didn’t promise new capabilities, it mapped where systems hold up. PNAS suggests learned cortical control can transfer beyond its training context. The motor-unit paper shows a limit: firing-rate structure stays rigid during neurofeedback. PD-stim pushes dual-site tACS toward real validation. FORCE1s makes two-photon voltage imaging work on standard microscopes. RE-MOVE is building a $24M closed-loop neuroprosthetics pipeline with ethics baked in from day one.

No demos, only infrastructure. The bottleneck isn’t decoding accuracy at the moment - it’s transfer, stability, and knowing where the system breaks before you put it in a person.

March was one of the more consequential months the field has had in a while. Not because of any single breakthrough, but because of what happened in aggregate: serious capital, a regulatory first, and big tech showing up with a foundation model. The commercialization phase isn’t coming… it’s here.

Money

Science Corp closed a $230M Series C at a $1.5B post-money valuation. The PRIMA retinal implant has a CE mark application in and a European launch expected mid-2026 (Germany). That would make Science Corp the first BCI company with a vision restoration product actually on the market.

Cognito Therapeutics raised $105M Series C to push its gamma-frequency Spectris headset through Alzheimer’s trials. New EEG data at AD/PD 2026 showed attenuation of EEG slowing. This signal is early, but it’s something to watch.

Smaller raises: Mave Health took in $2.1M for consumer neurotech wearables (focus and stress). MindMaze Therapeutics picked up a “Buy” rating from Baader Bank. This sell-side attention for a Swiss-listed neuro-rehab company is a meaningful signal.

Total capital deployed into the sector this month: north of $335M.

Regulation

The headline: Borui Kang Medical Technology received Chinese regulatory clearance for a minimally invasive extradural BCI targeting hand grasp restoration in quadriplegia. Widely reported as the first commercially authorized BCI medical device of its kind in the world.

Meanwhile, NeuCyber publicly stated it trails Neuralink by ~3 years. This is an unusually candid admission that reads more like strategic positioning than modesty. Beijing is building its neural-interface bench in public view.

On the non-invasive side: a multicenter RCT in Nature Digital Medicine provided solid clinical trial evidence for at-home tACS in depression. They did this by building on Flow Neuroscience’s FDA approval for at-home tDCS late last year. The at-home neuromodulation category is real.

Research Worth Knowing

Meta’s TRIBE model is the thing people are talking about most. Meta AI introduced a foundation model for neural decoding that achieves 70x resolution gains in cross-individual, cross-language decoding via in-silico simulation. Big tech is no longer sitting on the sidelines.

Handwriting BCI: A Nature Communications paper showed that motor cortex encodes handwriting as a full multidimensional movement: 3D velocity, grip force, pressure, EMG. Incorporating all of those features meaningfully improved decoding. This demonstrated that the signal is richer than the interface has been capturing.

Ultrasound wristband: A non-invasive wrist-worn device used AI to decode 22 degrees of freedom in real-time hand tracking from muscle and tendon kinematics. 22 DoF non-invasively is a number that should get your attention.

Closed-loop neuromodulation had a strong month. EEG-gated rTMS and adaptive MI-BCI difficulty both advanced; the trend toward tighter integration between decoding and stimulation is compounding.

MI-BCI methods: New architectures including DSSICNN (graph-attention spectral), polarity-aware microstates, and MEAN multimodal fusion (EEG+ECG+EOG). The non-invasive decoding stack keeps getting better.

The Actual Bottleneck

Commentary this month correctly put the spotlight on decoder training — the data requirements, the calibration burden per subject, the lack of generalization across individuals. Meta’s TRIBE is partly a response to this. So is the cross-participant encoding work on transfer learning for cortical mapping. The implant question is mostly answered. The decoder question is not.

Further Reading

• Personalized tES: computational modeling and optimization — JNE

• Open-access fNIRS finger movement dataset — Frontiers

• Bayesian hippocampal decoding for spatial memory — JNE

• Xi-alphaNET: alpha-wave slowing and white-matter decline — Neuroscience News

This week marked another step away from flashy demos toward real infrastructure.

The strongest signals came from a Chinese invasive‑BCI megaround, a new stroke‑focused implant startup, and two papers redefining “the signal”. One paper is on biocompatible materials grown inside living tissue, the other about layer‑specific origins of high‑gamma activity. It was also a week with clear warning signs on U.S. funding.

Three themes that stood out

1. Control is becoming co‑adaptive. Decoders and users learn each other in closed loop.

2. Capital is rewarding deployable products. Big money is following clear indications and regulatory paths.

3. Funding patience is eroding. Cuts to NIH and ARPA‑H threaten the slow, translational work BCI still needs.

China’s capital wave goes all‑in on invasive BCI

StairMed closes $72.8M financing

StairMed raised ¥500 M (~$73 M USD) co‑led by Alibaba and Tencent to scale its 256‑channel flexible implant, the first of its kind in China, and to launch ~40‑patient registration trials by mid‑2026.

Why it matters: Invasive BCI is now a multi‑geography industrial project, not a U.S. monopoly.

Read the coverage

Stroke rehab as a BCI beachhead

A New Implant Aims to Rewire the Brain to Help Stroke Patients

Epia Neuro, founded by Michel Maharbiz (ex‑iota Biosciences/Astellas), emerged from stealth with a minimally invasive implant that detects movement intent and drives a motorized rehab glove. First‑in‑human at Lenox Hill is slated for Q3 2026 via a 510(k) pathway.

Why it matters: This is an indication‑specific, regulator‑aligned product. Exactly the shape of mature neurotech.

Read the article

Redefining the interface itself

Blood‑catalyzed n‑doped polymers for reversible optical neural control

A Purdue team built conductive polymers inside living tissue using blood as the catalyst, achieving reversible, millisecond‑scale optical neural control in awake mice.

Why it matters: Interfaces grown from biology could solve the implant‑tissue mismatch that limits current hardware.

Read the paper

Distinct laminar origins of sensory‑evoked high‑gamma and low‑frequency ECoG

Optogenetic layer silencing showed that high‑gamma (65–450 Hz) arises primarily from Layer 5 pyramidal cells, while low‑frequency bands come from Layer 2/3.

Why it matters: Feature selection in ECoG decoders is a biological choice; this study tells you which layers carry your signal.

Read the paper

Policy backdrop turns colder

NIH would get $5 billion cut under 2027 budget

The White House proposal drops NIH to ~$41 B and slashes ARPA‑H by 37%. Even if blocked by Congress, the signal is clear: funding volatility is back.

Why it matters: BCI translation needs long‑cycle support just as public funding is tightening.

Read the STAT piece

Worth tracking

• Personalized TMS hits the hippocampus: Connectivity‑guided TMS causally modulates deep memory circuits. Nature Communications

• Continuous attractors for adaptive decoders: Fast domain transfer framework for online BCI calibration. Nature Comms Biology

• Cerebellar Engine co‑simulation: Spiking microcircuits embedded in a whole‑brain model for sensorimotor prediction. bioRxiv

• Reinforcement within‑trial motor adaptation: Learning updates occur inside trials, guiding BCI feedback design. Scientific Reports

• Wetware AI: Living neurons trained with FORCE learning to run chaotic math. Neuroscience News

• FDA AI Breakthrough Device standard tightens: Higher evidence bar for AI‑driven neurodevices. STAT News

My take

The week’s through‑line is maturity.

StairMed and Epia show capital and clinical focus coalescing around deployable indications. The Science and PNAS papers move beyond signals to materials and mechanisms. Policy signals warn that patience remains scarce.

BCI’s next phase won’t be about decoding accuracy alone. It’ll be about stability, adaptation, and building interfaces that last in the wild.

By the late 2000s, cochlear implants had become common. Hundreds of thousands of people worldwide had them. They were FDA-approved, covered by insurance, and standardized in surgery. Competing companies manufactured them. Meanwhile, another electrode approach was quietly gathering data that would change BCI design: grids of electrodes on the brain’s surface, recording unexpected signals.

In this post, I’ll discuss two trends from 2007 to 2010 that seemed unrelated then. The cochlear implant story shows how a neural interface matures. The ECoG story reveals a scientific surprise: the cortical surface carries richer signals than scalp EEG. This finding opened new design possibilities that the field still explores.

The cochlear implant precedent

Cochlear implants aren’t as flashy as intracortical BCIs. By the 1990s, the technology was mostly established as a microphone in the ear, an external speech processor, and an implanted electrode array stimulating the cochlea. The science was clear. By 2009, over 150,000 people globally had cochlear implants. The Nucleus 5, launched by Cochlear in September 2009, was the smallest behind-the-ear processor at that time. It was backward compatible for existing recipients. Several manufacturers (Cochlear, Advanced Bionics, MED-EL) were regularly updating their products. Insurance covered these devices, and surgeons had standardized protocols. Long-term safety data reached decades.

This story was largely ignored by the BCI field, but it should have been noted.

Cochlear implants worked not just because of the electrode or stimulation algorithm. They relied on a complete clinical framework: a clear patient population, measurable outcomes (like speech intelligibility), standardized surgery, and reimbursement options through Medicare and private insurers. The commitment to backward compatibility with the Nucleus 5 allowed implant recipients to upgrade without surgery. This was a significant engineering decision that signaled implants were a long-term investment.

The gap between cochlear implants and cortical BCIs is clear: cochlear technology interfaces with the compact, organized auditory nerve. In contrast, the motor cortex is far more complex. Still, the cochlear implant example proved that a long-term neural interface could be safe, manufacturable at scale, and economically viable. By 2010, DBS had reached about 80,000 patients worldwide for conditions like Parkinson’s disease and essential tremor. Together, these devices were the closest thing the neural interface field had to a clinical roadmap.

The core challenge for the BCI field during this time (and at present) was that no motor BCI had met these critical thresholds. There was no reimbursement pathway, no FDA approval for chronic cortical devices intended for home use, and no commercial company with sustainable revenue. The cochlear implant success highlighted this gap.

ECoG and the unexpected signal

The first clear evidence that electrocorticography (ECoG) could do more than previously assumed came in June 2004. Eric Leuthardt and his team at Washington University in St. Louis published in the Journal of Neural Engineering that four epilepsy patients could control a one-dimensional cursor using gamma-band ECoG signals. Training took three to twenty-four minutes, with success rates between 74% and 100%.

This result was striking for two reasons. First, the training time was much shorter than EEG-based motor imagery BCIs, which required weeks of practice. The ECoG method worked in minutes, indicating that the signals were cleaner. Electrodes placed on the surface of the brain provided higher signal-to-noise ratio and less interference than electrodes on the scalp. Second, ECoG captured high-gamma oscillations at 60–200 Hz, frequencies that carried substantial information about cortical processing, which conventional EEG recordings missed.

By 2005 and 2006, other researchers confirmed these findings. Gerwin Schalk and colleagues at the University of Washington extended the study to ten patients, showing that all subjects achieved control with accuracies between 73% and 100%. Their results revealed that ECoG control worked not just with motor imagery, but also with sensory imagery, speech imagery, and auditory cortex activation. This meant that even patients with extensive motor cortex damage might find usable signals on the cortical surface.

The comparison with intracortical recording is important. The Utah Array’s 96 electrodes penetrate 1–1.5 mm into the cortex, recording from individual neurons. This offers extraordinary resolution, allowing for real-time tracking of the activity of multiple neurons. However, penetration triggers an inflammatory response: microglia activate, leading to scar tissue formation and signal degradation. The Nagle trial had shown this degradation within months.

ECoG electrodes sit on the cortical surface without penetrating it. They record summed field potentials from thousands of neurons below each electrode. While spatial resolution is coarser, the inflammatory response is much less severe, showing more chronic stability. The cortical surface did not scar the electrode like the tissue interior did.

By 2009, Schalk and his team had demonstrated two-dimensional ECoG cursor control with accuracy comparable to single-unit intracortical systems. ECoG could decode two independent control dimensions with performance approaching that of the Utah Array, but without penetrating the cortex. This result clarified the “middle path” argument: ECoG offered better signal than scalp EEG and less surgical risk than intracortical arrays… but still required surgery.

Why the combination mattered

These two trends:

• cochlear implants at scale

• ECoG as a middle-path modality

were important for the field’s self-understanding.

Cochlear implants illustrated that the design requirements for a neural interface were well-known. A viable device must work for patients at home, not just in labs. Surgical procedures must be standardizable across many centers. Reimbursement must make the economics feasible for hospitals and patients. The hardware must last decades, and software should be updatable without surgery. None of these were research challenges; they were engineering, regulatory, and business issues. Yet by 2010, no motor BCI had addressed any of these.

ECoG revealed that the design possibilities for cortical BCIs were broader than the intracortical-versus-EEG binary suggested. A middle path offered better signal fidelity than scalp recordings without the chronic issues that made Utah Array longevity uncertain. The results from Leuthardt and Schalk began pointing toward speech and language decoding, where the cortical surface has dense, organized functional representations that ECoG could utilize. This connection would become a productive thread in BCI research for the next decade.

The key insight was the design tension the field began to articulate: go deep for higher resolution, accepting inflammatory risks; or stay on the surface for durability, accepting lower resolution. This tension remains unresolved but has been productively explored. The Stentrode from Synchron addresses this; it is an electrode array mounted on a stent deployed into a cerebral blood vessel. Precision Neuroscience’s thin-film subdural array offers another answer. Both products from the 2020s stem from the ECoG insights of 2004–2010: penetration isn’t always necessary for useful signals.

What was still uncertain

While ECoG’s chronic stability looked better than intracortical arrays, it was largely untested over long periods relevant to BCI use. The epilepsy monitoring studies that generated most ECoG BCI data involved temporary implants lasting a few weeks. It remained unknown if a chronic subdural ECoG implant would remain stable over years without gliosis, electrode-tissue degradation, or clinical complications. No approved chronic ECoG devices existed… yet.

Source material

Yearly reviews

• 2007 review

• 2008 review

• 2009 review

• 2010 review

Monthly feeds (key months)

• 2007-04

• 2008-03

• 2008-09

• 2009-06

• 2010-01

• 2010-06

Topic pages

• ecog-speech-syntax-decoding-sentence-production

• ecog-high-gamma-somatosensory-perceived-intensity

• ecog-guidewire-256-large-area

• micro-ecog-chronically-stable-motor-decoding

• wireless-subdural-ecog-65k-electrodes

• wireless-ecog-headstage-home-cage-primates

• neuroprosthetics-and-rehabilitation

• neuroprosthetics-market

• bci-clinical-translation-pathway

• soft-abi-brainstem-implant-hearing

Not every week in neurotech delivers a headline-grabbing implant milestone (this one didn’t). But it did surface a pattern that matters: some of the most credible progress is happening in the infrastructure layer. Topics touched include on-device decoding, portable neuromodulation, better calibration, and interfaces that reduce friction rather than maximize sci-fi.

The top research news this week was a wireless bidirectional neural interface. It moves spike decoding onto the device itself. This might seem like a small detail, but it addresses a major challenge in real-world BCI systems. If decoding relies on an external computer, untethered and practical implants remain limited.

Meanwhile, the neurotech landscape continued to evolve. China approved a new commercial BCI device. Science Corp secured more funding for its retinal implant program. Cognito gained financing and shared new EEG-linked Alzheimer’s data.

Though this week had fewer “BCI company launch” announcements, it still provided valuable insights into the field’s direction.

Three themes that stood out

1. More computation is moving onto the device.
   That’s where implantable systems need to go if they’re going to become practical outside tightly controlled lab settings.

2. Portable neuromodulation keeps gaining clinical credibility.
   This week’s tACS trial for depression reveals a trend. At-home stimulation systems are now becoming regulated products, not just experiments.

3. The most practical interfaces may not be purely brain-first.
   The best control results happened when we combine different physiological signals. A wrist-worn ultrasound system was used to decode motor intent. This method didn’t rely only on the brain.

The big story: on-device decoding gets more real

A bidirectional neural interface with direct on-device neuromorphic decoding for closed-loop optogenetics

The most important paper this week, in my view, was a new wireless bidirectional neural interface. A compact headstage combined recording, stimulation, and an on-chip neuromorphic spike decoder. The headline is architectural: the decoding happens on the device rather than being offloaded to an external computer. A lot of “closed-loop” neural systems are only closed-loop in a limited lab sense. Once the computation has to leave the device, you introduce latency, hardware bulk, and practical constraints that make the system much harder to translate.

If you care about next-generation implantable BCIs, this is the kind of paper worth paying attention to. It addresses the real bottleneck of fitting meaningful real-time decoding into miniaturized wireless hardware.

Better hardware is not enough by itself. The field also needs better deployment of decoding.

Read the paper

Clinical signal: portable stimulation keeps advancing

A multicenter randomized clinical trial of portable tACS for major depressive disorder

One of the more consequential translational papers this week is a multicenter randomized clinical trial. They used portable transcranial alternating current stimulation to treat major depressive disorder.

For readers interested in neurotech products and regulations, its significance goes beyond depression. The field is exploring whether non-invasive brain stimulation can move out of specialist clinics and into more practical deployment models. This evidence helps shapes that answer.

I see this as part of a larger body of evidence, not just a single turning point. However, it shows that portable neuromodulation is gaining recognition in neurotech.

The most scalable neurotech products may arrive through portable stimulation sooner than through high-profile implants.

Read the study

Adaptive difficulty in motor-imagery BCI training after stroke

A small but important clinical paper looked at using distance-to-bound to change task difficulty during motor-imagery BCI training for stroke patients.

The idea is simple: many motor-imagery BCIs are too hard for users, especially in rehab settings. Here, neural signals can be weak, inconsistent, or hard to classify. If the system can gauge how distinct a user’s signal is from the classifier boundary, it can adjust difficulty. This makes the training loop more adaptive and user-friendly.

This study involves only two cases, so it shouldn’t be overstated. However, it tackles a key issue: not whether MI-BCIs work, but if enough people can actually use them.

Usability is a major hurdle in clinical BCI, and adaptive training offers a promising solution.

Read the paper

A broader pattern: multimodal and peripheral interfaces keep getting stronger

EEG + ECG + EOG for attention classification

A new paper on multimodal attention-classification introduces a deep-learning model. This model combines EEG, ECG, and EOG signals instead of focusing only on EEG.

This approach is significant. Non-invasive BCI has long aimed for cleaner decoding from noisy EEG alone. However, in many real-world applications, it may be better to merge signals from different physiological sources. Each type can fill in the gaps left by the others, making the overall system stronger than one focused solely on the brain.

The future of practical non-invasive BCI may rely on multimodal systems, not just EEG.

Read the paper

A wrist-worn ultrasound interface that decodes hand intent

A new paper on multimodal attention-classification introduces a deep-learning model. This model uses EEG, ECG, and EOG signals together, rather than focusing only on EEG.

This approach is important. Non-invasive BCI has struggled with noisy EEG data. In many real-world cases, merging signals from different sources may work better. Each signal type can compensate for the others, making the system stronger than one that relies only on brain signals.

The future of non-invasive BCI may depend on multimodal systems, not just EEG.

Read the coverage

Field context: what happened outside of research

The research feed this week was lighter on classic company and regulatory headlines than the broader neurotech news cycle. A few developments are worth layering on top of the paper roundup:

• China approved a commercially authorized BCI device. China’s NMPA has cleared the first invasive BCI medical device. This system, from Shanghai’s Borui Kang Medical Technology, aims to help quadriplegia patients regain hand grasp, including through robotic-glove control (Reuters, MobiHealthNews). This is significant for two reasons. First, it shows that commercialization can happen outside the most popular companies or regions. Second, it raises competition in the implant and neuromodulation fields.

• Science Corp raised $230 million. Science Corp completed a $230 million Series C to advance its PRIMA retinal implant program. This funding will support U.S. trials and pending regulatory decisions (press release, STAT). This is important even if your focus is on BCI instead of vision restoration. It shows that investment continues in neurotechnology platforms with clear regulatory paths.

• Cognito raised roughly $105 million and added EEG-linked Alzheimer’s data. Cognito Therapeutics raised about $105 million in a popular Series C to further its gamma-frequency Spectris system for Alzheimer’s disease. They presented data at AD/PD 2026 showing reduced EEG slowing in treated patients (press release, Fierce Biotech). This connects to this week’s EEG-focused research. It shows that brain-signal biomarkers are becoming part of real products and trials.

• Neuralink continues to frame 2026 as a scale-up year. Reporting on Neuralink highlights plans for larger device production and more automated surgical workflows by 2026 (Reuters, Business Insider). Regardless of your view on that timeline, it shapes the conversation about implantable interfaces.

Worth tracking

• Meta’s TRIBE AI: a big-tech push toward cross-individual neural decoding and foundation-model-style brain-response prediction.
  Read the coverage

• Spike sorting evaluation gets more rigorous: a Journal of Neurophysiology paper introduces effect sizes and statistical power analysis for benchmarking sorting algorithms.
  Read it

• Automated TMS thresholding could reduce setup friction: RMT-Finder proposes an automated method for determining resting motor threshold from MEP amplitudes.
  Read it

• Resting EEG + HRV can decode cognitive state: another sign that passive and multimodal decoding may be more practical than task-heavy paradigms in some settings.
  Read it

• DBS target selection in Parkinson’s gets a network-level lens: a Molecular Psychiatry paper compares how GPi versus STN stimulation modulate inter-hemispheric dynamics.
  Read it

• DBS for treatment-resistant depression stays on the radar: chronic implanted neuromodulation is steadily expanding beyond movement disorders.
  Read the coverage

• Time-varying DCM for slow cortical potentials: methodologically interesting for anyone thinking about non-stationary control signals in BCI.
  Read it

• Transformer embeddings for aphasia recovery: worth watching for speech prostheses and language-model-informed neurotech.
  Read it

• Cross-participant encoding models: another attack on the decoder-calibration problem.
  Read it

• Representational drift during learning: relevant to adaptive decoders that need to survive non-stationary neural signals over time.
  Read it

My take

This week wasn’t full of big BCI news. Still, it showed some important changes.

The real progress didn’t come from bold claims about mind reading or quick consumer brain interfaces. It came from better hardware, smoother stimulation, multimodal decoding, and systems that tackle control issues in practical ways.

While this may not be flashy, it’s likely more predictive.

If the last few years focused on proving neural interfaces can work, the next years will challenge us further. We need to make them portable, easy to calibrate, manufacturable, and practical outside demos.

This week felt like a glimpse into that future.

On June 22, 2004, a 25-year-old man named Matthew Nagle had 96 electrodes pressed into his motor cortex and, within weeks, moved a cursor across a screen using only his thoughts. The public saw a paralyzed man playing Pong with his mind. What the field saw was something more specific: proof that cortical motor neurons survive years of disuse, remain tuned to intended movement, and can be decoded in real time.

In this post, I’m tracing how BCI got from primate labs to the first human clinical trial. That transition, from “it works in monkeys” to “it works in a person”, took most of the early 2000s, and it required a particular convergence of electrode hardware, decoding software, FDA approval, and one extraordinary patient willing to test all of it. I’ll also cover the parallel non-invasive track running alongside intracortical work, because the two paths shaped each other in ways that still matter.

This is the research spine underneath this series: bci0.neural-noise.xyz. The yearly reviews from 2003–2006 are where I pulled the specific dates and papers below.

The primate foundation

Before there was a human trial, there were over a decade of experiments in monkeys. By 2003, three labs - Miguel Nicolelis at Duke, John Donoghue at Brown, and Andrew Schwartz at Pittsburgh - had spent years characterizing how populations of motor cortex neurons encoded intended limb movements. The culminating paper of that primate era came in October 2003: Carmena et al. in PLOS Biology, showing that rhesus monkeys with multi-electrode arrays spanning motor cortex, premotor cortex, somatosensory cortex, and posterior parietal cortex could control a robot arm to reach and grasp. The signals from this array of sensors could be used to decode position, velocity, and gripping force simultaneously, in real time, in closed loop.

That wasn’t just a technical step. It demonstrated that:

1. the motor cortex carried enough information for multi-parameter control

2. that monkeys could learn to use this feedback

3. and that cortical reorganization accompanied that learning.

This set the benchmark that human systems would have to approach.

Cyberkinetics Neurotechnology Systems, the Brown University spin-off co-founded by Donoghue and colleagues in 2001, spent 2003 in active FDA discussions, building the case for an Investigational Device Exemption. Their device: the Utah Microelectrode Array1 had been tested in 22 monkeys. The question was whether it would work in a human brain that had been injured and deprived of movement for years.

Matthew Nagle and the BrainGate pilot

On June 22, 2004, neurosurgeon Gerhard Friehs implanted the 96-electrode array into the hand and arm region of Matthew Nagle’s right motor cortex at Rhode Island Hospital in Providence. Nagle was 25 years old, paralyzed from the neck down after a stabbing injury in 2001. The FDA IDE had been confirmed in April.

Six weeks after surgery, calibration began. Nagle was asked to imagine moving his hand in different directions. The decoder, running on software adapted from BCI20002, immediately found modulated neural activity. Nagle reportedly said “Holy shit!” when he saw the cursor respond.

Over 57 sessions at New England Sinai Hospital (July 2004 through April 2005), he learned to open simulated email, change TV channels, draw circular shapes in a paint program, operate a prosthetic hand, and play “neural Pong.” What he was doing wasn’t elegant… the system required a bulky external hardware cabinet, a trained technician, and daily recalibration. But the fundamental finding was unambiguous: motor cortex neurons in a person with years of cervical spinal cord injury retained directional tuning and temporal modulation suitable for real-time decoding. The cortex hadn’t gone quiet.

A second participant received an implant at the University of Chicago in April 2005. A third received her implant in late 2005 or early 2006. Her data would eventually show useful neural recordings more than 1,000 days post-implant, a counter-narrative to the signal degradation story that dominated the field after Nagle.

The full peer-reviewed results came in Nature on July 13, 2006. The Hochberg, Serruya, Friehs, and Donoghue paper formally introduced BrainGate to the scientific record. The same issue contained another landmark: Santhanam, Ryu, Yu, Afshar, and Shenoy at Stanford reporting 6.5 bits per second from premotor cortex plan activity in monkeys (4x improvement over prior systems), and the first time a BCI had demonstrated information rates competitive with existing assistive communication alternatives. Two papers in one issue defined the field’s dual agenda for the next decade: clinical feasibility on one side, performance on the other.

The parallel non-invasive track

While BrainGate was working through FDA approvals and clinical enrollment, a different BCI tradition was building its own infrastructure. It was more reproducible, more accessible, and in some ways more practically useful in the near term.

The Graz BCI group, led by Gert Pfurtscheller, had spent years demonstrating that imagined hand and foot movements produced distinctive patterns in scalp EEG - specifically in the mu and beta sensorimotor rhythms. By 2003, their system achieved classification accuracies up to 100% in trained subjects using just two bipolar EEG channels and linear discriminant analysis. They were already testing it in paraplegic patients with hand orthoses. The paradigm was fundamentally different from intracortical work: no surgery, no foreign body response, no FDA IDE required… but also far less spatial resolution and far lower signal fidelity.

At the Wadsworth Center in Albany, Jonathan Wolpaw and Dennis McFarland were pursuing P300-based spellers and, separately, sensorimotor rhythm cursor controllers. Their December 2004 PNAS paper settled a long-standing question: EEG-based sensorimotor rhythms could support accurate two-dimensional cursor control in humans. Independent control of both horizontal and vertical dimensions (using mu rhythm for one axis, beta rhythm for the other) was possible with careful signal processing and a co-adaptive algorithm that improved in parallel with the user. This directly answered the critics who argued EEG’s resolution was inherently too limited for multi-dimensional BCI.

The field also built shared infrastructure during this period that proved essential. BCI2000, published by Schalk and colleagues at Wadsworth in IEEE Transactions on Biomedical Engineering in June 2004, standardized real-time EEG recording, feature extraction, and feedback delivery into a modular, shareable platform. By 2007 it would be running at more than 80 research centers globally. The BCI Competition 20033 created the field’s first rigorous cross-laboratory benchmark. BCI Competition III in 2005 followed, this time including ECoG data. These competitions did for BCI what ImageNet would later do for computer vision: forced the community to compete on shared ground.

Why this decade mattered

The 2003–2006 period established several things that the field would build on for the next two decades.

First: cortical motor decoding was feasible in humans, not just primates. Nagle’s trial settled that. Even a brain that had been deprived of movement feedback for three years retained motor cortex neurons capable of driving a decoder. That was not guaranteed before 2004.

Second: the academic-to-clinical-trial template was established. The path from Donoghue’s Brown lab to the Cyberkinetics IDE to Friehs’ surgery to Hochberg’s clinical trial management became the model. Every major intracortical trial since has followed a version of it.

Third: the regulatory and ethical frameworks for chronically implanted neural devices began to take shape. The BrainGate IDE, and the FDA’s willingness to grant it, created precedent. Informed consent protocols, adverse event reporting, and the definition of “clinical benefit” for a BCI were all worked out in practice during these trials.

Fourth: the funding ecosystem activated. NIH’s NINDS neural prosthetics program was supporting the major invasive labs throughout this period. DARPA was beginning to increase its investment under the Human Assisted Neural Devices program. The Society for Neuroscience 2004 meeting featured noticeably expanded BCI sessions from Schwartz, Shenoy, Andersen, and the European groups. This signaled that the field was no longer a niche within a niche.

What was still uncertain

Signal longevity was the central unsolved problem. Nagle’s recordings declined significantly by month six or seven. This was due to astrocytic encapsulation, neuronal retreat from the electrode tips, the brain’s foreign-body response to rigid silicon. Groups at Michigan, Utah, and MIT were already exploring flexible polymer electrodes and anti-inflammatory surface coatings, but there were no solutions yet. The field didn’t know whether useful recordings would last six months or six years in a given patient, or why the variability was so high.

Whether cursor control would translate to functional independence was also genuinely open. Nagle’s demonstrations were striking, but the system required a technician, a hardware cabinet, and daily recalibration. It wasn’t something a person could use at home. The gap between a controlled clinical demonstration and a device someone could rely on for communication or motor control was wide, and the field was only beginning to understand how wide.

And there was no business model. Cyberkinetics was struggling to raise the $40–50 million Donoghue and CEO Timothy Surgenor estimated they needed to commercialize. By 2007, the company had largely wound down its BrainGate investment. They were unable to attract the capital a genuinely novel, high-risk medical device required before it had clear clinical outcomes data, regulatory approval, or a reimbursement pathway. The BrainGate pilot had been a scientific success and a commercial near-failure.

The invasive-versus-non-invasive question was also unresolved. Intracortical systems offered far higher signal quality but carried surgical risk and the chronic recording problem. EEG was safe and accessible but limited. And then, in 2004, a third option had appeared: Eric Leuthardt and colleagues at Washington University published the first demonstration that electrocorticographic signals (subdural electrode strips on the cortical surface, not penetrating it) could enable one-dimensional cursor control with training times of just three to twenty-four minutes, achieving success rates of 74–100%. That result opened a design space nobody had fully mapped yet.

The bridge forward

By the end of 2006, BCI had a peer-reviewed proof of principle in a human patient, two competing information-theoretic benchmarks, a global software platform, a generation of algorithms sharpened by public competitions, and a field-defining open problem in signal longevity. What it didn’t have was a second neural interface success story at scale… a device that had made it all the way through through the clinical and commercial gauntlet.

That story already existed. It just wasn’t in motor cortex. Cochlear implants had been reaching patients since the 1980s and were already in hundreds of thousands of ears worldwide. And a surface electrode approach (ECoG) was about to show that the cortex held far more signal than anyone had expected, without the penetration that caused the longevity problem. Both threads reshaped how the BCI field thought about its own future. That’s the next post.

Source material

Yearly reviews

• 2003 review

• 2004 review

• 2005 review

• 2006 review

Monthly feeds (key months)

• 2003-06 - early BCI methods landscape

• 2004-06 - around BrainGate pilot

• 2004-07

• 2005-03

• 2006-07 - Nature publication period

Topic pages

• bci-and-neural-decoding

• motor-imagery-eeg-bci

• intracortical-bci-chronic-stroke-neural-signal-analysis

• bci-clinical-translation-pathway

• bci-communication-restoration-paralysis

• bci-robotic-arm-paralyzed-patient

• chronic-neural-probes-materials-design

• deep-learning-neural-decoding-bci

• blackrock-neurotech

BCI progress is becoming an execution problem, not a headline problem.

Most people read this week as a mixed bag: a few methods papers, a few China-vs-Neuralink headlines, some market noise. I read it differently. The signal is coherent: practical BCI progress is moving toward deployability and timing, while market and geopolitical narratives are getting louder than primary evidence.

If that framing is right, the edge now comes from building systems that are robust in real workflows, not from chasing the next impressive demo clip.

My thesis this week

Three things are converging:

1. Timing is causal: closed-loop timing is beating fixed schedules in stimulation contexts.

2. Usability is technical debt: near-invisible interfaces matter as much as model quality for real adoption.

3. Narrative pressure is rising: competitive timeline claims are spreading faster than auditable technical detail.

1) Methods are getting more deployable

The strongest pair this week sits in the Journal of Neural Engineering:

• Near-invisible c-VEP for passive workload monitoring tackles a real adoption bottleneck: visually intrusive stimuli.

• Brain-state-dependent rTMS uses EEG alpha ERD gating to time stimulation against neural state, rather than fixed schedules.

This is exactly the direction I want to see: methods that survive contact with real environments.

• Near-invisible c-VEP-based passive BCI for mental workload monitoring

• Brain state dependent repetitive transcranial magnetic stimulation improves motor learning outcomes

2) Decoding and neuromodulation are both getting more mechanistic

Two other papers reinforce the same shift:

• Polarity-considered microstates push EEG feature engineering beyond coarse aggregate summaries.

• Precision neuroimaging of DBS-modulated circuits shows frequency- and time-dependent divergence across networks.

Neither is a product release. Both are exactly the kind of mechanism-level progress that eventually changes product reliability.

• Polarity-considered EEG microstates improve classification accuracy of oddball stimulus

• Mapping deep brain stimulation-modulated circuits via precision neuroimaging

3) The China-Neuralink narrative is now a market artifact

The “three years behind Neuralink” claim appears across Reuters and multiple syndications. That does not make it false, but it does make it a narrative object first and a technical object second.

My default stance:

• Treat this as a competitive signaling event (important).

• Do not treat it as an independently audited benchmark (not yet).

• Beijing-backed brain chip firm says it is 3 years behind Musk’s Neuralink - Reuters

• Chinese brain chip project speeds up human trials after first success - Reuters

4) Markets and partnerships: signal, but not substitute evidence

I separate this bucket into two lanes:

• Execution adjacency: Paradromics academic collaboration is meaningful if it translates to real partner throughput and validation loops.

• Market visibility: Ceribell and MindMaze items are useful for commercial context, not scientific proof.

For consumer neurotech, Mave’s raise is demand signal, not efficacy signal.

• Paradromics launches academic collaboration programme for BCI advancement - Medical Device Network

• CeriBell, Inc. (CBLL) Reports Q4 Loss, Beats Revenue Estimates - Nasdaq

• Mave Health Raises $2.1M to Launch Focus and Stress Regulation Wearable - Business Wire

If I were building in this space right now

I would make four bets:

1. Build timing-native systems: treat state-gated intervention as baseline, not premium.

2. Optimize for invisibility: reduce user-facing friction in passive interfaces first.

3. Demand source hierarchy: separate primary methods evidence from market/media echo.

4. Track commercialization pathways: partnerships and financials matter, but only when tied to verifiable technical milestones.

What would change my mind

I would revise this thesis if fixed-schedule interventions consistently matched closed-loop outcomes in high-quality replications, or if “narrative-heavy” competitive claims started arriving with robust public technical disclosures.

Right now, this week’s evidence still favors deployability and evidence discipline over hype velocity.

Full weekly rundown (including additional neuromodulation, decoding, and basic science papers):

https://bci0.neural-noise.xyz/2026-week-12

Quiet week for headlines, strong week for core methods and clinical foundations. No major company news, but several papers with direct implications for how we design decoders, stimulation protocols, and modeling pipelines.

Handwriting BCI: add dimensions

Cortical representation of multidimensional handwriting movement and implications for neuroprostheses in Nature Communications

Shows motor cortex encodes handwriting as a multidimensional motor act (strokes vs. lifts, 3D kinematics, force, pressure, muscle-like activity), not just 2D pen velocity. Including these dimensions improves decoding. For communication BCIs, this argues for expanding the motor target space rather than relying on 2D trajectories plus language modeling.

DBS: circuits and outcomes

Circuit response to neuromodulation characterized with simultaneous DBS and precision neuroimaging in humans in Nature Neuroscience
Longitudinal 3T MRI with DBS over ~1 year maps which circuits are engaged by stimulation and how responses evolve. Provides circuit-level data needed for principled closed-loop DBS.

Predictors of motor outcome with pallidal stimulation for Parkinson’s disease from the CSP468 cohort in npj Parkinson’s Disease
Identifies two key predictors for GPi-DBS motor outcome: overlap with a primary-motor GPi “sweetspot” and pre-op levodopa response, validated in an independent cohort.

Modeling & stability

Charge Based Boundary Element Method with Residual Driven Adaptive Mesh Refinement for High Resolution Electrical Simulation Modeling in bioRxiv
Adaptive BEM-FMM refinement around electrodes and tissue boundaries improves EEG/TES forward-model accuracy without prohibitive mesh sizes.

Oligodendrocyte-specific fus depletion preserves CA1 single-unit fidelity and stabilizes network dynamics during chronic recording in Journal of Neural Engineering
Altering oligodendrocyte/myelin biology stabilizes single-unit signals and network dynamics over long-term hippocampal recordings, suggesting a biological route to more stable chronic implants.

Large-scale dynamics & state features

Global coincident bursts of high frequency oscillations across the human cortex coordinate large-scale memory processing in Nature Communications
Global HFO bursts (60–800 Hz) co-occur across widespread cortex and predict successful encoding/recall, supporting the use of global event-like features in addition to local power for cognitive-state decoding.

Human claustrum neurons encode uncertainty and prediction errors during aversive learning in bioRxiv
Rare human claustrum single-unit recordings show encoding of uncertainty and prediction error, pointing to a more explicit computational role in model updating.

Open datasets

• Open access individual finger movement dataset with fNIRS - Non-invasive benchmark for finger-movement decoding.

• A human EEG dataset to study cognitive flexibility during auditory discrimination under real-world distractors - EEG + MRI + forward models for distraction and reorientation under naturalistic sounds.

Week in numbers

• Papers included/triaged: 21/152

• Open datasets: 2

• Company/industry news: 0

Full weekly rundown (including additional methods, neuromodulation, and basic-science papers): https://bci0.neural-noise.xyz/feeds/weekly/2026-week-11

Bottom line: No splashy demos, but several papers that change “how you should build”, especially the handwriting work (expand the target), the DBS work (measure circuits over time), and the forward-modeling advance (better physics upstream makes everything downstream less fragile).

Back next week. If you spotted something I missed, hit reply.

In this first Neural Noise post, I aim to:

1. Highlight key developments in 2025.

2. Set the tone for the kind of writing I’ll share here.

This isn't a detailed annual review; that’s in the research spine underneath. Instead, it’s how I’d explain the year to someone smart, busy, and curious about the future of BCI and neurotech.

In short, 2025 made the field harder to dismiss and summarize.

It became harder to dismiss because more stories were about real devices, patients, approvals, and care pathways. Precision Neuroscience received FDA clearance for a minimally invasive implant. Paradromics hit a first-in-human milestone and later got FDA approval for its Connect-One speech trial. Neuralink continued its implants and expanded trial sites. The University of Michigan Health opened one of the first dedicated BCI clinics in the U.S. The focus shifted from “interesting lab” work to “how does this get used?”

It also became harder to summarize because the field was no longer a single story.

• The speech story featured brain-to-voice systems, inner-speech decoding, and tools for those who lost their speech.

• The hardware story highlighted denser arrays, wireless systems, and design trade-offs about invasiveness and durability.

• The non-invasive story showed finer motor control, serious device efforts, and the need for non-invasive methods.

• The governance story included neuroprivacy, neural data protection, UNESCO’s ethics standard, and debates over inferences allowed before full normalization.

1. BCI moved closer to the clinic

For years, neurotech was easy to label as "promising, but not yet." In 2025, that changed.

The shift wasn’t a single product; it was the emergence of a complete stack. Devices, trials, regulators, clinics, and patient stories began interacting. FDA clearances for Precision's implant and ONWARD’s ARC-EX, along with Paradromics’ trial approval, made it harder to keep this in the "someday" category. Neuralink’s many implants, Synchron’s Stentrode, and Ceribell’s EEG reinforced that this field is now competing for patients, talent, and capital.

This is what maturity looks like: not certainty, but infrastructure.

2. Speech became the clearest application wedge

If you asked which application best explains the year, I’d say speech and communication.

We saw brain-to-voice neuroprostheses, handwriting decoded from stable neural states, and ECoG work on sentence timing. WVU’s first BCI test for speech, Stanford’s real-time inner-speech decoding, and Neuralink’s planned trial for speech impairment pushed the field from “cool demo” to recognizable product paths. Paradromics’ FDA-approved trial and growing datasets filled the pipeline from invasive to non-invasive, and from English to tonal languages.

Restoring communication is vital. The need is real. When a field can explain its value clearly, it becomes easier to build, regulate, fund, and critique.

3. Governance stopped being a side conversation

One reason I keep returning to neurotechnology is the link between technical progress and governance. If devices can decode speech or infer intention, privacy and consent are essential. They are product, clinical, and legal questions.

In 2025, the ethics conversation became hard to ignore. A neural data bill in Congress, the proposed MIND Act, and UNESCO’s global standard on neurotechnology ethics brought the debate into the open. Secure-pairing work for implants and clinician views on explainability showed these concerns are shaping device and trial design.

A field this ambitious shouldn’t mature in private. 2025 was the first year it felt broadly understood.

What I still want answers on

I don’t think 2025 resolved key issues; it sharpened them. I want clearer answers on durability, usability, and performance in everyday settings. The gap between "excellent demo" and "repeatable product" remains blurred. Non-invasive methods need to prove enduring value, not just novelty. The field is just starting to take neural data rights seriously.

I want to follow the field closely while stepping back to see the larger pattern. In 2025, the pattern became clear: invasive paths to clinics, speech as a wedge, non-invasive systems seeking essential roles, and governance moving to the forefront.

It feels like the right moment to start sharing this journey publicly. Thank you for reading.

Most BCI coverage swings between breakthrough headlines and vague futurism. Neural Noise is my attempt at something better: rigorous, readable, and useful.

Here’s what you can expect:

• Clear explanations of core BCI and neurotech ideas, built from first principles when it helps

• Evidence-first analysis of what’s real, what’s early, and what’s uncertain

• Practical synthesis that gives you a better mental model of the field

I’ll publish monthly (at least) to start. Each issue is built to be worth your time in a single sitting.

If that sounds useful, subscribe and share this with one person who follows neurotechnology.

::paolo